Status:
COMPLETED
Corneal Crosslinking Treatment Study
Lead Sponsor:
Region Skane
Conditions:
Progressive Keratoconus
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Three different protocols for inducing corneal crosslinks in subjets with progressive keratoconus will be evaluated in this randomised clinical study.
Detailed Description
Riboflavin does not penetrate the intact corneal epithelium. Corneal cross linking (CXL) is typically performed using the so-called "Dresden protocol". The Dresden protocol states 30 minutes of UVA-ra...
Eligibility Criteria
Inclusion
- Progress in keratoconic eye. We define progress as an increase in Kmax of 1.0 diopter in 1 year or 0.5 diopter in 6 months. This increase in Kmax will be accepted as progression if concomitant changes tomographic parameters.
Exclusion
- Concurrent ocular infection or corneal disease other than keratoconus.
- Pregnancy.
- Treatment with Isotretinoin.
Key Trial Info
Start Date :
May 23 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 19 2024
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04427956
Start Date
May 23 2017
End Date
November 19 2024
Last Update
November 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skåne University Hospital
Lund, Skåne County, Sweden, 22242